Bronstein, Gewirtz & Grossman LLC Announces Class Action Lawsuit for Investors in Bolt Biotherapeutics, Inc. Who Suffered Substantial Losses!

NEW YORK, July 3, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) and certain of its officers.

Class Definition

This lawsuit seeks damages against the defendants for alleged violations of federal securities laws on behalf of all persons and entities who purchased or otherwise acquired Bolt securities between February 5, 2021And May 14, 2024inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the Company’s website: bgandg.com/BOLT.

Case details

The complaint alleged that throughout the Class Period, Defendants made materially false and misleading statements about the Company’s business, operations and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had presented to investors and was in fact unlikely to meet its predefined success criteria; (ii) as a result, Defendants overstated the clinical and/or commercial prospects of Bolt’s product pipeline, upon which the Company relies primarily to sustain its business model; (iii) all of the foregoing exposed the Company to an increased risk of disruptive management transitions and substantial workforce reductions; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

And after?

A class action has already been filed. If you would like to view a copy of the complaint, you can visit the firm’s website: bgandg.com/BOLT or you can contact Master Peretz Bronstein or its Customer Relations Manager, Nathan Millerof Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you have suffered a loss at Bolt, you have up to September 3, 2024to ask the court to appoint you as lead plaintiff. Your ability to share in any recovery does not require that you serve as lead plaintiff.

It costs you nothing

We represent investors in class actions on a contingency fee basis. This means that we will ask the court to reimburse us for costs and attorneys’ fees, typically a percentage of the total amount recovered, only if we are successful in our case.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm representing investors in securities fraud class actions and shareholder derivative actions. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Lawyer Advertising. Past results do not guarantee similar results.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein Or Nathan Miller
332-239-2660 | (protected email)

SOURCE Bronstein, Gewirtz & Grossman, LLC